SLC8A2

Across TCGA pan-cancer cohorts, SLC8A2 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated SLC8A2 data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher SLC8A2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC8A2 expression acts as an unfavorable survival marker, although some lineages such as BLCA and UCEC show a favorable association.

THYM, BLCA, and LUSC are the cancer types where SLC8A2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
BLCA	OS	Median	II,III,IV	1.000	0.400	.003	38	view →
LUSC	DFS	Median	All	0.132	0.400	.001	33	view →
LUAD	OS	Median	II,III,IV	0.209	0.685	<.001	10	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
KIRP	OS	Median	All	0.105	0.688	.004	6	view →
UCEC	DFS	Median	All	0.924	0.627	.045	2	view →
SKCM	DFS	Median	All	0.090	0.213	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

SLC8A2–THYM (OS)

Open the THYM breakdown →